


Buckely et al. referenced on page 13, line 11 and page 13, line 12 through line 22. Pioglitazone and rosiglitazone are disclosed on page 5, line 30, and page 9, line 7. Dose ranges for the relevant molecules are discussed on page 6, line 4, page 7, line 10 through 22, page 10, line 18 through 27, page 15, line 1 through 5 and page 17, line 3 through page 18. A concentration range for GLP-1 molecules in a composition are disclosed on page 15, line 11. Controlled release preparations are discussed on page 15, line 12 through 26. Page numbers referenced herein refer to published PCT application WO 00/7833.

**Response to Restriction Requirement:**

The Examiner requires restriction of Claims 1 through 22. Applicants elect Group 1 drawn to a method of treating non-insulin dependent diabetes using an incretin hormone and a TZD. Applicants have cancelled Claims 1 through 22. New Claims 23 through 56 are drawn to a method of treating non-insulin dependent diabetes using a GLP-1 agonist and two specific TZDs. There are no composition claims in the newly amended claim set. The Examiner identified four species of TZDs and requires election of a single species. Applicants elect pioglitazone. Claims 23, 24, and 26 through 56 read on the elected species.

Respectfully submitted,



Mark J. Stewart  
Attorney for Applicants  
Registration No. 43,936  
Phone: 317-276-0280

Eli Lilly and Company  
Patent Division/MJS  
P.O. Box 6288  
Indianapolis, Indiana 46206-6288

October 23, 2002